Zhen Zhao

Zhen Zhao

Auto-generated profile, based on publicly available information

Zhen Zhao

Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, USA

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2013 in Cell
Verified
Journal Article
Closed access
ALAmaia Lujambio
Amaia Lujambio
LALeila Akkari
Leila Akkari
JSJanelle Simon
Janelle Simon
DGDanielle Grace
Danielle Grace
DTDarjus F. Tschaharganeh
Darjus F. Tschaharganeh
SLScott W. Lowe
Scott W. Lowe

1 May 2014 in Cancer Cell
Verified
Journal Article
Closed access
CCChong Chen
Chong Chen
YLYu Liu
Yu Liu
ARAmy R. Rappaport
Amy R. Rappaport
TKThomas Kitzing
Thomas Kitzing
NSNikolaus Schultz
Nikolaus Schultz
SLScott W. Lowe
Scott W. Lowe

12 May 2023 in Science
Verified
Journal Article
Open access
CBCassandra Burdziak
Cassandra Burdziak
DADirena Alonso-Curbelo
Direna Alonso-Curbelo
TWThomas Walle
Thomas Walle
JRJosé Reyes
José Reyes
FBFrancisco M. Barriga
Francisco M. Barriga
DPDana Pe’eR
Dana Pe’eR
The response to tumor-initiating inflammatory and genetic insults can vary among morphologically indistinguishable cells, suggesting as yet uncharacterized roles for epigenetic plasticity during early neoplasia. To investigate the origins and impact of such plasticity, we performed single-cell analyses on normal, inflamed, premalignant, and malignant tissues in autochthonous models of pancreatic cancer. We reproducibly identified heterogeneous cell states that are primed for diverse, late-emerging neoplastic fates and linked these to chromatin remodeling at cell-cell communication loci. Using an inference approach, we revealed signaling gene modules and tissue-level cross-talk, including a neoplasia-driving feedback loop between discrete epithelial and immune cell populations that was functionally validated in mice. Our results uncover a neoplasia-specific tissue-remodeling program that may be exploited for pancreatic cancer interception.

1 September 2014 in Cell Reports
Verified
Journal Article
Open access
JBJessica E. Bolden
Jessica E. Bolden
NTNilgun Tasdemir
Nilgun Tasdemir
LDLukas E. Dow
Lukas E. Dow
JEJohan H. van Es
Johan H. van Es
JWJohn E. Wilkinson
John E. Wilkinson
SLScott W. Lowe
Scott W. Lowe
BET family proteins are novel therapeutic targets for cancer and inflammation and represent the first chromatin readers against which small-molecule inhibitors have been developed. First-generation BET inhibitors have shown therapeutic efficacy in preclinical models, but the consequences of sustained BET protein inhibition in normal tissues remain poorly characterized. Using an inducible and reversible transgenic RNAi mouse model, we show that strong suppression of the BET protein Brd4 in adult animals has dramatic effects in multiple tissues. Brd4-depleted mice display reversible epidermal hyperplasia, alopecia, and decreased cellular diversity and stem cell depletion in the small intestine. Furthermore, Brd4-suppressed intestines are sensitive to organ stress and show impaired regeneration following irradiation, suggesting that concurrent Brd4 suppression and certain cytotoxic therapies may induce undesirable synergistic effects. These findings provide important insight into Brd4 function in normal tissues and, importantly, predict several potential outcomes associated with potent and sustained BET protein inhibition.

14 September 2022 in Science Translational Medicine
Verified
Journal Article
Open access
SCSteven T. Chen
Steven T. Chen
MPMatthew Park
Matthew Park
DVDiane Marie Del Valle
Diane Marie Del Valle
MBMark Buckup
Mark Buckup
ATAlexandra Tabachnikova
Alexandra Tabachnikova
MMMiriam Merad
Miriam Merad
Although it has been more than 2 years since the start of the coronavirus disease 2019 (COVID-19) pandemic, COVID-19 continues to be a worldwide health crisis. Despite the development of preventive vaccines, therapies to treat COVID-19 and other inflammatory diseases remain a major unmet need in medicine. Our study sought to identify drivers of disease severity and mortality to develop tailored immunotherapy strategies to halt disease progression. We assembled the Mount Sinai COVID-19 Biobank, which was composed of almost 600 hospitalized patients followed longitudinally through the peak of the pandemic in 2020. Moderate disease and survival were associated with a stronger antigen presentation and effector T cell signature. In contrast, severe disease and death were associated with an altered antigen presentation signature, increased numbers of inflammatory immature myeloid cells, and extrafollicular activated B cells that have been previously associated with autoantibody formation. In severely ill patients with COVID-19, lung tissue–resident alveolar macrophages not only were drastically depleted but also had an altered antigen presentation signature, which coincided with an influx of inflammatory monocytes and monocyte-derived macrophages. In addition, we found that the size of the alveolar macrophage pool correlated with patient outcome and that alveolar macrophage numbers and functionality were restored to homeostasis in patients who recovered from COVID-19. These data suggest that local and systemic myeloid cell dysregulation are drivers of COVID-19 severity and modulation of alveolar macrophage numbers and activity in the lung may be a viable therapeutic strategy for the treatment of critical inflammatory lung diseases.

1 February 2019 in Cancer Discovery
Verified
Journal Article
Closed access
PDF file
GKGnana P. Krishnamoorthy
Gnana P. Krishnamoorthy
NDNatalie R Davidson
Natalie R Davidson
SLSteven D. Leach
Steven D. Leach
ZZZhen Zhao
Zhen Zhao
SLScott W. Lowe
Scott W. Lowe
JFJames A. Fagin
James A. Fagin
Translation initiation is orchestrated by the cap binding and 43S preinitiation complexes (PIC). Eukaryotic initiation factor 1A (EIF1A) is essential for recruitment of the ternary complex and for assembling the 43S PIC. Recurrent EIF1AX mutations in papillary thyroid cancers are mutually exclusive with other drivers, including RAS. EIF1AX mutations are enriched in advanced thyroid cancers, where they display a striking co-occurrence with RAS, which cooperates to induce tumorigenesis in mice and isogenic cell lines. The C-terminal EIF1AX-A113splice mutation is the most prevalent in advanced thyroid cancer. EIF1AX-A113splice variants stabilize the PIC and induce ATF4, a sensor of cellular stress, which is co-opted to suppress EIF2α phosphorylation, enabling a general increase in protein synthesis. RAS stabilizes c-MYC, an effect augmented by EIF1AX-A113splice. ATF4 and c-MYC induce expression of amino acid transporters and enhance sensitivity of mTOR to amino acid supply. These mutually reinforcing events generate therapeutic vulnerabilities to MEK, BRD4, and mTOR kinase inhibitors. Significance: Mutations of EIF1AX, a component of the translation PIC, co-occur with RAS in advanced thyroid cancers and promote tumorigenesis. EIF1AX-A113splice drives an ATF4-induced dephosphorylation of EIF2α, resulting in increased protein synthesis. ATF4 also cooperates with c-MYC to sensitize mTOR to amino acid supply, thus generating vulnerability to mTOR kinase inhibitors. This article is highlighted in the In This Issue feature, p. 151